Fluphenazine Hydrochloride

CHEMBL1448187 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

510.4 g/mol

LogP

—

Phase

4

This hydrochloride salt of fluphenazine is an oral antipsychotic used in the treatment of schizophrenia and psychotic disorders by blocking dopamine receptors in the brain. It requires careful dose adjustment to balance therapeutic effects with movement-related side effects.

Molekularmasse

510,4000 g/mol

TPSA

55,30 Å²

Therapeutische Bereiche

Schizophrenia Generalized Anxiety Disorder Psoriasis

Wirkmechanismus

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

Cl.Cl.OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1

InChI

InChI=1S/C22H26F3N3OS.2ClH/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29;;/h1-2,4-7,16,29H,3,8-15H2;2*1H

Molecular Formula

C22H28Cl2F3N3OS

HBD / HBA

3 / 8

Rotierbare Bindungen

6

Schwere Atome

32

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

This hydrochloride salt of fluphenazine is an oral antipsychotic used in the treatment of schizophrenia and psychotic disorders by blocking dopamine receptors in the brain. It requires careful dose adjustment to balance therapeutic effects with movement-related side effects.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Fluphenazine Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1448187. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 67356. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Fluphenazine Hydrochloride auf PillFYI

Struktur

Schnelldaten

Formel: C22H28Cl2F3N3OS
Synonyme: 1

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.